

## Technology Advisory Interests Register

**Topic: Iptacopan for treating complement 3 glomerulopathy [ID6283]**

**Publication Date: TBC**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Lewis Brimble	Expert	Direct - non-financial	He is currently enrolled onto the extension study for this treatment.	18/03/2025	It was agreed that Lewis's declaration would not prevent them from providing expert advice to the committee
		Direct - financial	I have received travel expenses from Novartis in relation to study visits to hospital, and I have received an honorarium from Novartis to act as a patient expert for them.	13/08/2025	
Professor David Kavanagh	Expert	Direct - financial	Alexion/ Astra Zenica: Research Grant £ 179,777.50 & Conference travel Sobi: £4,347.58 Advisory boards Novartis: £5,466.88 - Steering committee member, FDA Advisory Committee nominee advisor, EU rapporteur, Advisory boards/Lectures Silence therapeutics: £1,550.79 - Advisory Boards Roche: £600.00 Advisory Boards Sanofi: £4,071.60 Advisory Boards Purespring therapeutics: £1,925.00 Advisory Boards	17/03/2025	It was agreed that David's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Professor Matthew Pickering		Direct - financial	<p>Participation (with personal remuneration) in multiple Scientific and Clinical Advisory Boards for Pharma including advisory board for Novartis (11/Nov/2024).</p> <p>Also note I have previous and ongoing paid roles with Sobi (the company developing pegcetacoplan in Europe and UK) and previous paid roles with Apellis (the company developing pegcetacoplan for the US). For SOBI work this included attendance at a recent clinical advisory board (Frankfurt, 17/March/2025); a planned industry-sponsored symposium at the ERA-EDTA meeting in Vienna in 06/June/2025 and participation in an Educational event with MEDSCAPE sponsored by SOBI (to be recorded 06/June/2025).</p>	31/03/2025	It was agreed that Matthew's declaration would not prevent them from providing expert advice to the committee